Cell Free DNA, Endometriosis
Conditions
Keywords
Endometriosis, cell free DNA, oocyte quality
Brief summary
Endometriosis is a common benign disease in premenopausal women and causes chronic pelvic pain and infertility. This infertility may be due to pelvic adhesions and surgery but also because of poor oocyte quality. It is known that endometriosis is associated with an increase oxidative stress, wich induce chronic inflammation, deleterious effect for DNA, proteins and can caused cellular death. ROS markers found in follicular fluid or in serum are significatively higher in endometriosis women. The investigators want to dose a marker of apoptosis in infertile women and see if it's significatively higher in serum and in follicular fluid of patients with endometriosis compared to others infertility causes and if it's correlated to oocyte quality and IVF results. Real time PCR will be used to dose cell free DNA in serum and follicular fluid of patients undergoing IVF treatment (endometriosis and infertility due to tubal factor, male infertility or idiopathic cause). Then the investigators will compare cell free DNA rate with oocyte and embryo quality and with pregnancy outcomes in the different group.
Interventions
BIOLOGICALblood sample
10ml of blood will be sampled from patients before undergoing IVF treatment, the cell free DNA will be extracted and then quantified by a real time PCR. Another 10ml sample will be drawn the day of oocyte puncture for a new quantification of cell free DNA in plasma and cell free DNA will also be dose in follicular fluid of patients
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 43 Years
Healthy volunteers
No
Inclusion criteria
* patients eligible medical assistance to procreation who are about to undergo IVF treatment * aged between 18 and 43 years old * and who have signed a consent form
Exclusion criteria
* patients who are not eligible for medical assistance to procreation, * patients who are followed for other inflammatory disease, * patients followed for premature ovarian failure or * patients with a recent story of pelvic infection
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cell free DNA rate in serum in patients before they start IVF stimulation | day 1 | cell free DNA in serum quantified by real time PCR in patients before they start IVF stimulation |
| cell free DNA rate in follicular fluid the day of punction | day 1 | cell free DNA in follicular fluid the day of punction |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| number of live birth in both groups | 1 year | — |
| number of oocytes reaching the metaphase II | 1 year | number of oocytes reaching the metaphase II in both groups of patients |
| blastulation rate at day 5 of developement | day 5 | blastulation rate at day 5 of developement |
| number of cells at day 2 | day 2 | number of cells at day 2 |
| number of cells at day 3 | day 3 | number of cells at day 3 |
| fragmentation rate | 1 year | fragmentation rate |
| number of clinical pregnancy in both groups | 1 year | — |
Countries
France
Outcome results
None listed